Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* has HCV RNA ≥10,000 IU/mL in peripheral blood at the time of screening~* has documented chronic HCV GT1 or GT3 infection~* has either negative or positive history of liver cirrhosis based on liver biopsy, Fibroscan, or FibroSure ® (Fibrotest®)~* is treatment naïve to all anti-HCV treatment~Exclusion Criteria:~* has evidence of decompensated liver disease~* is coinfected with hepatitis B virus (e.g. hepatitis B surface antigen positive) or human immunodeficiency virus~* has a history of malignancy ≤5 years prior to signing informed consent, or is under evaluation for other active or suspected malignancy~* has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC~* has clinically-relevant drug or alcohol abuse within 12 months of screening~* has any of the following conditions: organ transplants other than cornea and hair, poor venous access that precludes routine peripheral blood sampling, history of gastric surgery or malabsorption disorders, or any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial~* has a history of chronic hepatitis not caused by HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GT1:NC Grazoprevir/Elbasvir+SOF 4wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC with SOF 400mg once daily (q.d.) by mouth for 4 weeks (n=30 planned).
- GT1:NC Grazoprevir/Elbasvir+SOF 6wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=30 planned).
- GT1:C Grazoprevir/Elbasvir+SOF 6wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=20 planned).
- GT1:C Grazoprevir/Elbasvir+SOF 8wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=20 planned).
- GT3:NC Grazoprevir/Elbasvir+SOF 8wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=15 planned).
- GT3:NC Grazoprevir/Elbasvir+SOF 12wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=15 planned).
- GT3:C Grazoprevir/Elbasvir+SOF 12wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=10 planned).

Based on this trial design, predict the completion outcome and termination type (if applicable).